Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in Lymphoma
Loading...
Date
2010
Authors
Özet, Ahmet
Ataergin, Selmin
Arpacı, Fikret
Kuzhan, Okan
Kömürcü, Şeref
Öztürk, Bekir
Öztürk, Mustafa
Journal Title
Journal ISSN
Volume Title
Publisher
Karger
Abstract
Objective: Our purpose was to investigate the efficacy of and establish a toxicity profile for a modified regimen of dexamethasone, cytarabine and cisplatin (DHAP) for lymphoma outpatients. Subjects and Methods: Fifty-one lymphoma patients, 26 with Hodgkin's disease and 25 with non-Hodgkin's lymphoma, were included. The patients' median age was 32 years (range: 17-61). Twenty had progressive/refractory disease and 31 relapsed disease. Twenty-five were in clinical stage I/II and 26 in clinical stage III/IV before the initiation of salvage chemotherapy. DHAP consisted of dexamethasone (40 mg i.v. on days 1-4), cytarabine (2 g/m(2) i.v. as 3-hour infusion on days 2 in the evening and 3 in the morning) and cisplatin (35 mg/m(2) as 2-hour infusion on days 1-3) were administered every 21 days. A total of 154 cycles of modified DHAP were administered, with a median of 3 cycles per patient (range: 2-4). Results: The main toxicity was myelosuppression. WHO grade III-IV neutropenia and grade III-IV thrombocytopenia were observed in 27 (52.9%) and 21 (41%) patients, respectively. The overall response rate (85% for Hodgkin's disease and 95% for non-Hodgkin's lymphoma) was 88.3% (39.2% complete response and 49.1% partial response). Conclusion: The results showed that this outpatient schedule of DHAP was well tolerated and an effective salvage regimen.
Description
Keywords
Dexamethasone, cytarabine and cisplatin, Non-Hodgkin's lymphoma, Hodgkin's disease, Salvage chemotherapy, Effective salvage therapy, Disease, Transplantation, Cytoreduction, Chemotherapy, Ifosfamide, Etoposide, ESHAP, DHAP, General & internal medicine
Citation
Kanat, Ö. vd. (2010). "Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in Lymphoma". Medical Principles and Practice, 19(5), 344-347.